Breaking News Instant updates and real-time market news.

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

, EYEN

Eyenovia

$2.89

0.04 (1.40%)

18:58
07/15/19
07/15
18:58
07/15/19
18:58

Fly Intel: After Hours Movers

UP AFTER EARNINGS: JB Hunt (JBHT) up 7.1%. ALSO HIGHER: Eyenovia (EYEN) up 6.0% after disclosing CEO bought 234K shares of stock... Viking Therapeutics (VKTX) up 1.2% after being initiated with Outperform at Oppenheimer. DOWN AFTER EARNINGS: Arrow Electronics (ARW) down 5.3% after below-consensus Q2 pre-announcement. ALSO LOWER: Anterix (ATEX) down 6.0% after equity offering... Repligen (RGEN) down 3.4% after equity offering... Medical Properties Trust (MPW) down 3.2% after equity offering. Movers as of 18:30ET.

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

EYEN

Eyenovia

$2.89

0.04 (1.40%)

VKTX

Viking Therapeutics

$8.25

0.02 (0.24%)

ARW

Arrow Electronics

$68.82

-0.15 (-0.22%)

ATEX

Anterix

$47.61

0.61 (1.30%)

RGEN

Repligen

$85.87

0.86 (1.01%)

MPW

Medical Properties Trust

$18.28

-0.23 (-1.24%)

  • 15

    Jul

  • 24

    Jul

  • 25

    Jul

  • 06

    Aug

  • 08

    Aug

  • 09

    Aug

  • 26

    Aug

  • 09

    Sep

  • 18

    Sep

  • 19

    Sep

  • 13

    Nov

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

JBHT J.B. Hunt
$92.50

-0.45 (-0.48%)

07/11/19
DBAB
07/11/19
NO CHANGE
DBAB
Deutsche makes sell 'Catalyst Call' on J.B. Hunt, buy on XPO and Knight-Swift
Deutsche Bank analyst Amit Mehrotra initiated a "Catalyst Call" sell on J.B. Hunt (JBHT) and buys on both XPO Logistics (XPO) and Knight-Swift Transportation (KNX). The analyst made the short-term investment ideas into the Q2 earnings season. He thinks J.B. Hunt's results could serve as a catalyst for "broad-based" negative earnings revision for the company. For XPO, Mehrotra believes the company's Q2 results will mark a positive inflection point in sentiment. For Knight-Swift, the analyst thinks consensus estimates for Q4 are too low.
07/11/19
FBCO
07/11/19
DOWNGRADE
FBCO
Neutral
J.B. Hunt downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Allison Landry downgraded J.B. Hunt to Neutral from Outperform saying that with a weakening demand backdrop, contract TL rates that are turning negative, and anecdotal evidence that suggests capacity remains relatively loose, she sees fairly meaningful risk to the second half of 2019 and 2020 EPS for the asset based truckers.
07/10/19
07/10/19
DOWNGRADE

Hold
CSX, Canadian Pacific downgraded to Hold from Buy at Loop Capital
As previously reported, Loop Capital analyst Rick Paterson downgraded CSX (CSX) and Canadian Pacific (CP) to Hold from Buy as part of a broader Air Freight & Logistics industry research note, saying the freight transportation data continue to indicate a slowing in the industrial economy. The analyst cites volumes registering a second consecutive quarter of negative growth relative to their prior years, with the most recent quarter also declining sequentially from the prior one and the upcoming quarter likely remaining pressured by the tough annual comps. The analyst also lowers his price targets on Canadian Pacific to C$338 from C$340, CSX to $81 from $85 while also reducing the price targets on UPS (UPS) to $128 from $145, J.B. Hunt (JBHT) to $121 from $133, and Hub Group (HUBG) to $65 from $71.
07/10/19
GSCO
07/10/19
INITIATION
Target $113
GSCO
Buy
J.B. Hunt initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Jordan Alliger started J.B. Hunt with a Buy rating and a $113 price target. The analyst notes that while the company is faced with "significant headwinds" in its main intermodal business, he also sees the "adverse trends" that impacted profits in 2019 reversing through 2020. Alliger contends that J.B. Hunt could be at the "forefront" of turnaround stories in the Air Freight & Logistics industry.
EYEN Eyenovia
$2.89

0.04 (1.40%)

01/30/19
LTCO
01/30/19
NO CHANGE
Target $35
LTCO
Buy
MIST-1 positive results provide further de-risking of Eyenovia's programs, says Ladenburg
Ladenburg analyst Matthew Kaplan notes that Eyenovia announced this morning that the MIST-1 Phase 3 study met its primary endpoint showing statistically significant superiority over the single-agent active control arms. The analyst believes the positive results from the MIST-1 study provide further de-risking of Eyenovia's programs by demonstrating strong efficacy of microdosing, and it is also an important validation of the platform delivery technology. This is particularly meaningful since all the programs use the same fundamental delivery microdose technology, he notes, adding that he looks forward to the readout of the topline Phase 3 results for the MIST-2 study in the near-term, and the presentation of the detailed results from the MIST-1 and MIST-2 trials at a medical conference later this year. Kaplan reiterates a Buy rating and a $35 price target on the shares.
04/24/19
OPCO
04/24/19
INITIATION
Target $9
OPCO
Outperform
Eyenovia initiated with an Outperform at Oppenheimer
Oppenheimer initiated Eyenovia with an Outperform and $9 price target.
04/25/19
OPCO
04/25/19
INITIATION
Target $9
OPCO
Outperform
Oppenheimer bullish on Eyenovia, initiates with an Outperform
As previously reported, Oppenheimer analyst Esther Rajavelu started coverage of Eyenovia with an Outperform rating and a $9 price target. As its business model targets cash-pay customers initially, and third-party payers over the longer term, the analyst believes the company may be well positioned to generate a diversified stream of revenues with varying margin profiles.
04/25/19
04/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Frontdoor (FTDR) initiated with an Outperform at Raymond James. 2. Sage Therapeutics (SAGE) initiated with a Buy at Jefferies. 3. Eyenovia (EYEN) initiated with an Outperform at Oppenheimer. 4. DXP Enterprises (DXPE) initiated with a Hold at Jefferies. 5. Replimune Group (REPL) initiated with an Outperform at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VKTX Viking Therapeutics
$8.25

0.02 (0.24%)

07/15/19
OPCO
07/15/19
INITIATION
Target $12
OPCO
Outperform
Viking Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson initiated Viking Therapeutics with an Outperform rating and $12 price target, citing his view that the company has a validated approach to nonalcoholic steatohepatitis, or NASH. He estimates lead asset VK2809 can have total worldwide peak unadjusted sales of $2.2B and he sets a 35% probability of success for the drug.
06/25/19
STFL
06/25/19
INITIATION
Target $14
STFL
Buy
Viking Therapeutics initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Viking Therapeutics with a Buy rating and $14 price target, citing his belief that the IND for VK2809 will be accepted and his view that concerns around the drug's tolerability profile are unwarranted. He is confident that the FDA will allow Viking to initiate a Phase 2b study in biopsy proven non-alcoholic steatohepatitis patients, Archila tells investors.
06/25/19
STFL
06/25/19
INITIATION
Target $126
STFL
Hold
Madrigal Pharmaceuticals initiated with a Hold at Stifel
Stifel analyst Derek Archila initiated Madrigal Pharmaceuticals (MDGL) with a Hold rating and $126 price target, stating that he is positively biased heading into Phase 3 amid emerging evidence that point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. However, he thinks the stock could be volatile around updates from competitors such as Viking Therapeutics (VKTX) and Genfit (GNFT) and sees few catalysts specific to Madrigal to drive shares up in the next 12-18 months, Archila tells investors.
05/15/19
WBLR
05/15/19
NO CHANGE
WBLR
Outperform
Viking Therapeutics risk/reward symmetry skewed to upside, says William Blair
William Blair analyst Andy Hsieh reiterates an Outperform rating on Viking Therapeutics (VKTX) after hosting investor meetings the company's CEO Brian Lian. The analyst continues to view Viking's risk/reward symmetry as skewed to the upside, especially with the recent sector volatility and the "continued significant valuation gap" with competitor Madrigal Pharmaceuticals (MDGL). Viking is on track to file an investigational new drug application later this year to the FDA's Division of Gastroenterology and Inborn Errors Products, which would enable the company to initiate the Phase II biopsy-confirmed nonalcoholic steatohepatitis study, Hsieh tells investors in a research note.
ARW Arrow Electronics
$68.82

-0.15 (-0.22%)

07/02/19
RAJA
07/02/19
DOWNGRADE
Target $80
RAJA
Outperform
Arrow Electronics downgraded, Avnet estimates cut after checks at Raymond James
As previously reported, Raymond James analyst Adam Tindle downgraded Arrow Electronics (ARW) to Outperform from Strong Buy and he also lowered his estimates for fellow component distributor Avnet (AVT) following his semiconductor checks. His estimates for Arrow came down by about 10%, prompting the downgrade in rating and a lowering of his price target on the stock to $80 from $88. He lowered his estimates for Avnet by about 6% and maintains his $52 price target on its shares along with keeping a Strong Buy rating on the stock.
07/02/19
RAJA
07/02/19
DOWNGRADE
RAJA
Outperform
Arrow Electronics downgraded to Outperform from Strong Buy at Raymond James
07/11/19
STFL
07/11/19
NO CHANGE
Target $15
STFL
Hold
Vishay price target lowered to $15 after pre-announcement at Stifel
After Vishay (VSH) pre-announced June quarter sales and gross margins that came below its previous guidance, citing weaker demand, primarily from distribution, Stifel analyst Matthew Sheerin said he thinks the news "should come as no surprise to investors" considering the recent negative tone from several component suppliers and distributors. However, the magnitude of Vishay's miss reflects a deeper correction and increased pricing pressure, said Sheerin, who thinks the correction could last well into the first half 2020. Given the warning, he lowered his estimates and cut his price target on Vishay shares to $15 from $18 and keeps a Hold rating on the stock. Sheerin added that he sees risks to estimates for a number of component suppliers, particularly those with high exposure to distribution, such as AVX (AVX), Kemet (KEM) and Littelfuse (LFUS), and to distributors Arrow Electronics (ARW) and Avnet (AVT).
06/20/19
CRSS
06/20/19
DOWNGRADE
CRSS
Hold
Arrow Electronics downgraded to Hold from Buy at Cross Research
Cross Research analyst Steven Fox downgraded Arrow Electronics to Hold from Buy.
ATEX Anterix
$47.61

0.61 (1.30%)

RGEN Repligen
$85.87

0.86 (1.01%)

11/05/18
HCWC
11/05/18
NO CHANGE
Target $60
HCWC
Neutral
Repligen price target raised to $60 from $49 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Repligen to $60 but reiterates a Neutral rating on the name. Solid execution produced a "modest beat" in Q3, but the stock reaction may have been overdone, Selvaraju tells investors in a research note. He believes the stock "still looks expensive."
11/12/18
KING
11/12/18
DOWNGRADE
KING
Neutral
Repligen downgraded to Neutral from Buy at CL King
CL King analyst David Westenberg downgraded Repligen to Neutral from Buy.
12/17/18
12/17/18
UPGRADE
Target $65

Buy
Follow-up: Repligen upgraded to Buy on valuation at CL King
As previously reported, CL King upgraded Repligen to Buy from Neutral with a $65 price target. Analyst David Westenberg said shares are now trading at a "reasonable" valuation with near-term drivers looking positive.
12/17/18
KING
12/17/18
UPGRADE
KING
Buy
Repligen upgraded to Buy from Neutral at CL King
MPW Medical Properties Trust
$18.28

-0.23 (-1.24%)

07/02/19
07/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CenterPoint Energy (CNP) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Insoo Kim saying the recent underperformance of CenterPoint shares "over-penalizes the company's robust utility growth profile" that comprises around 70% of consolidated earnings. 2. Dova Pharmaceuticals (DOVA) upgraded to Outperform from In Line at Evercore ISI. 3. Landstar System (LSTR) upgraded to Market Perform from Underperform at Raymond James with analyst Patrick Brown saying the stock's risk/reward is more balanced at current levels. 4. Cars.com (CARS) upgraded to Buy from Neutral at Citi with analyst Nicholas Jones saying the stock's current valuation is low "even if we were to exclude the probability for an acquisition." 5. Medical Properties Trust (MPW) upgraded to Buy from Hold at SunTrust with analyst Michael Lewis saying he thinks the company has an opportunity to take advantage of a large acquisition pipeline and attractive cost of capital to drive above-average earnings growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/02/19
RHCO
07/02/19
UPGRADE
Target $20
RHCO
Buy
Medical Properties Trust has strong growth, some defense, says SunTrust
SunTrust analyst Michael Lewis upgraded Medical Properties Trust to Buy from Hold and raised his price target to $20 from $19. In a research note to investors, Lewis says he thinks the company has an opportunity to take advantage of a large acquisition pipeline and attractive cost of capital to drive above-average earnings growth. While he thinks the company's recent international deals will make money, he expects domestic deals in the second half of 2019 to have higher cap rates more "pleasing" to investors.
07/02/19
RHCO
07/02/19
UPGRADE
RHCO
Buy
Medical Properties Trust upgraded to Buy from Hold at SunTrust
02/13/19
JEFF
02/13/19
UPGRADE
Target $23
JEFF
Buy
Jefferies sees 'strong wave' of deals for Medical Properties, upgrades to Buy
Jefferies analyst Omotayo Okusanya upgraded Medical Properties Trust to Buy from Hold and raised his price target for the shares to $23 from $18. The company last week announced an $859M acquisition of 11 Australian hospitals, leading management to increase fiscal 2019 acquisition guidance to $2.5B from $2.0B prior, Okusanya tells investors in a research note. The analyst believes "this is the start of a strong wave of acquisitions over the next 12 months." He says Medical Properties Trust's valuation "still screens cheap" despite its "superior" growth profile.

TODAY'S FREE FLY STORIES

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

21:22
08/19/19
08/19
21:22
08/19/19
21:22
Initiation
Sunnova Energy initiated at KeyBanc »

Sunnova Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
08/19/19
08/19
20:54
08/19/19
20:54
Periodicals
Trump administration considering steps on economy if conditions worsen, NYT says »

White House officials…

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$48.20

2.69 (5.91%)

, TJX

TJX

$51.55

0.13 (0.25%)

20:25
08/19/19
08/19
20:25
08/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KSS

Kohl's

$48.20

2.69 (5.91%)

TJX

TJX

$51.55

0.13 (0.25%)

MDT

Medtronic

$104.15

1.42 (1.38%)

HD

Home Depot

$207.98

4.335 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 04

    Sep

  • 09

    Sep

BHP

BHP Group

$49.12

0.31 (0.64%)

19:32
08/19/19
08/19
19:32
08/19/19
19:32
Hot Stocks
BHP Group sees China and global economic growth slowing »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BHP

BHP Group

$49.12

0.31 (0.64%)

19:25
08/19/19
08/19
19:25
08/19/19
19:25
Earnings
BHP Group reports FY19 Net profit up 124% at $8.31B »

Reports FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AAPL

Apple

$210.32

3.88 (1.88%)

19:09
08/19/19
08/19
19:09
08/19/19
19:09
Periodicals
Apple aims for November launch of Apple+, Bloomberg reports »

Apple is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$195.19

2.005 (1.04%)

19:04
08/19/19
08/19
19:04
08/19/19
19:04
Hot Stocks
Accenture acquires Parker Fitzgerald, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Baidu…

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ET

Energy Transfer LP

$13.77

0.3 (2.23%)

18:40
08/19/19
08/19
18:40
08/19/19
18:40
Periodicals
Energy Transfer LP performing maintenance on WTG pipeline, Reuters says »

A spokeswoman for Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.32

3.88 (1.88%)

, SNE

Sony

$55.71

-0.01 (-0.02%)

18:20
08/19/19
08/19
18:20
08/19/19
18:20
Periodicals
Apple allocates over $6B for original TV shows and movies, FT says »

Apple (AAPL) has budgeted…

AAPL

Apple

$210.32

3.88 (1.88%)

SNE

Sony

$55.71

-0.01 (-0.02%)

NFLX

Netflix

$309.40

6.66 (2.20%)

DIS

Disney

$135.33

0.14 (0.10%)

T

AT&T

$35.40

0.42 (1.20%)

CBS

CBS

$44.21

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

LGIH

LGI Homes

$78.56

3.36 (4.47%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
LGI Homes opens two new communities in greater Seattle market »

LGI Homes announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
Amazon.com to expand in Utah with new new fulfillment center »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

WMT

Walmart

$113.76

0.77 (0.68%)

18:00
08/19/19
08/19
18:00
08/19/19
18:00
Hot Stocks
Walmart to pay $100,000 to settle EEOC disability discrimination suit »

Wal-Mart Stores East, LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

X

U.S. Steel

$12.42

1.13 (10.01%)

17:58
08/19/19
08/19
17:58
08/19/19
17:58
Periodicals
U.S. Steel to lay off hundreds of workers at Great Lakes plant, Reuters says »

U.S. Steel plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta falls over 4% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:52
08/19/19
08/19
17:52
08/19/19
17:52
Hot Stocks
FDA's CRL to Sarepta's golodirsen citing risk of infection, renal toxicity »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BSX

Boston Scientific

$42.74

0.59 (1.40%)

17:41
08/19/19
08/19
17:41
08/19/19
17:41
Hot Stocks
Boston Scientific's ImageReady MRI labeling receives FDA approval »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

, GOOG

Alphabet

$1,198.01

21.07 (1.79%)

17:35
08/19/19
08/19
17:35
08/19/19
17:35
Periodicals
State AGs to proceed with antitrust investigation of big tech, WSJ reports »

A group of state…

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

GOOG

Alphabet

$1,198.01

21.07 (1.79%)

GOOGL

Alphabet Class A

$1,199.94

21.25 (1.80%)

FB

Facebook

$186.22

2.8 (1.53%)

MSFT

Microsoft

$138.43

2.3 (1.69%)

AAPL

Apple

$210.32

3.88 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FB

Facebook

$186.22

2.8 (1.53%)

17:31
08/19/19
08/19
17:31
08/19/19
17:31
Periodicals
FTC head says breaking up Facebook could be complicated, FT reports »

Federal Trade Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

MPW

Medical Properties Trust

$18.28

0.13 (0.72%)

17:28
08/19/19
08/19
17:28
08/19/19
17:28
Hot Stocks
Medical Properties Trust COO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WMT

Walmart

$113.76

0.77 (0.68%)

17:17
08/19/19
08/19
17:17
08/19/19
17:17
Periodicals
Walmart's U.S. Chief Marketing Officer Barbara Messing is leaving, AdAge says »

Walmart U.S. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

MAXR

Maxar Technologies

$6.49

0.185 (2.93%)

17:12
08/19/19
08/19
17:12
08/19/19
17:12
Hot Stocks
Maxar Technologies' MDA awarded Canadian Space Agency contract »

MDA, a Maxar company, has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.30

0.21 (0.41%)

17:06
08/19/19
08/19
17:06
08/19/19
17:06
Hot Stocks
Rogers 'disappointed' by CRTC decision on broadband wholesale rates »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.10

1.02 (5.97%)

17:05
08/19/19
08/19
17:05
08/19/19
17:05
Hot Stocks
Breaking Hot Stocks news story on iQIYI »

iQIYI down over 6% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

17:03
08/19/19
08/19
17:03
08/19/19
17:03
Hot Stocks
iQIYI reports Q2 total subscribing members 100.5M, up 50% from last year »

iQIYI's number of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.